Review Examines Janus Kinase Inhibitors for Refractory Juvenile Idiopathic Arthritis

Janus kinase inhibitors selectively block intracellular signaling pathways to manage juvenile idiopathic arthritis and associated comorbidities that remain refractory to existing treatments, according to a peer-reviewed review published in BMC Rheumatology. Authors Anna Tryfonos, Jennifer L. Huggins, and Hermine I. Brunner assess both approved therapeutic options and agents with off-label use across this disease spectrum. As documented in the review, juvenile idiopathic arthritis is not a single uniform condition but rather a heterogeneous group of inflammatory arthritides encompassing at least six different categories.

Despite significant advancements in the clinical management and treatment of juvenile idiopathic arthritis, many cases of active arthritis fail to respond to current therapies. The authors highlight that this therapeutic resistance extends beyond joint pathology to major disease-associated comorbidities and extraarticular complications. In particular, chronic uveitis and interstitial lung disease represent serious comorbidities that frequently prove refractory to established treatment regimens.

Mechanistically, Janus kinase inhibitors—abbreviated as JAKi—are small molecules classified as target-specific disease-modifying antirheumatic drugs, or tsDMARDs. These therapeutic agents function by selectively inhibiting janus kinases, thereby directly blocking the Janus kinase and Signal Transducers and Activators pathway, commonly known as STAT. Through the targeted disruption of this intracellular pathway, the drugs prevent the downstream proinflammatory effects that typically follow its activation.

The review provides detailed clinical commentary on Janus kinase inhibitors that have received formal regulatory approval for treating juvenile idiopathic arthritis, while also discussing medications that are currently utilized with off-label use. In their analysis, Tryfonos, Huggins, and Brunner devote special consideration to the application of these small molecules in juvenile idiopathic arthritis accompanied by extraarticular manifestations and severe complications. By examining both approved and off-label Janus kinase inhibitors, the published review illustrates how targeting the Janus kinase pathway provides therapeutic strategies for managing refractory arthritis and its most challenging comorbidities, including interstitial lung disease and chronic uveitis.

Subject of Research: Janus kinase inhibitors in juvenile idiopathic arthritis

Article Title: Janus kinase inhibitors for the treatment of Juvenile Idiopathic Arthritis

Article References: Tryfonos, A., Huggins, J. L., & Brunner, H. I. (2026). Janus kinase inhibitors for the treatment of Juvenile Idiopathic Arthritis. BMC Rheumatology. https://doi.org/10.1186/s41927-026-00690-4

Image Credits: AI Generated

DOI: 10.1186/s41927-026-00690-4

Keywords: Janus kinase inhibitors, Juvenile Idiopathic Arthritis, JAK-STAT pathway, targeted DMARDs, chronic uveitis, interstitial lung disease, refractory arthritis, rheumatology, Janus, kinase, inhibitors, treatment